Sector News

French Smith & Nephew CEO Olivier Bohuon seen as solid pick for top Sanofi job

November 5, 2014
Life sciences
Olivier Bohuon, the CEO of artificial hip and knee maker Smith & Nephew may have a leg up over other potential candidates to take the reins of drugmaker Sanofi after the firing of Chris Viehbacher last week. He has experience in pharma and has excelled at Smith & Nephew by moving it into new markets. Most importantly, he is French.
 
“There’s a strong rationale for Sanofi to appoint him. He’s halfway through the job at Smith & Nephew and whether he wants to abandon that is a question, but Sanofi, for a Frenchman, would have very strong attractions,” Savvas Neophytou, an analyst at Panmure Gordon, told Reuters.
 
Serge Weinberg, chairman and now acting CEO, told analysts in a call last week that the Viehbacher’s nationality did not factor into the decision to can him. “It is important to note that all board members, regardless of nationality, voted for this decision,” he said. After preparing for upcoming launches, Weinberg said his second focus is to find as soon as possible, “a good pharma professional, whatever his nationality is.”
 
Still, it is generally believed that Viehbacher’s downfall could be traced to his frank discussions of Sanofi missteps, a tendency his less discursive French board abhorred, his lack of finesse in navigating French political and government protocol, and his seeming inability to realize his forthright style upset his bosses. The company’s first non-French CEO, Viehbacher was sometimes openly critical of the lack of innovation from its French operations. He lacked savoir faire.
 
But investors appreciated Viehbacher’s moves to focus Sanofi internationally. While Weinberg acknowledged Sanofi must be an international company, the firing worried some that the drugmaker might become insular.
 
Bringing the 55-year-old Bohuon on might dispel some of those concerns. He has a French education and was CEO of French pharmaceutical and cosmetics firm Pierre Fabre four years ago, Reuters points out. He also has lots of international experience. He ran the pharmaceutical business for Abbott Laboratories at one point and has worked for GlaxoSmithKline in Europe. Bohuon also has moved Smith & Nephew into sports medicine and emerging markets. Emerging markets were part of Viehbacher’s focus. Bohuon’s experience with devices might complement Sanofi’s efforts to sell more insulin by improving insulin delivery and testing devices.
 
Two other names have also surfaced among the matchmakers. AstraZeneca CEO Pascal Soriot has reportedly been approached but was not interested in a move. Bernard Poussot, the former boss of Wyeth who is now retired has also been mentioned. What is their appeal? Both have strong pharma experience and both have strong French connections.
 
By Eric Palmer
 

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”